Aim
To increase LDL-C testing and treatment awareness using Expert Consensus Decision Pathway-based care.
What is the aim of the ACC "Driving Urgency to Treat LDL-C" initiative?
Prompts/reminders, education, and a performance dashboard.
What methods does ACC"Driving Urgency to Treat LDL-C" use?
Clinicians in primary care and cardiology.
Who is the intended audience for the ACC "Driving Urgency to Treat LDL-C" initiative?
Participation in the Veradigm Practice Fusion EHR network.
What is required to join the "Driving Urgency to Treat LDL-C" initiative?
This initiative expects to improve lipid testing and treatment rates in patients with ASCVD.
What is ACC "Driving Urgency to Treat LDL-C"?
To improve LDL-C testing and treatment before ASCVD hospital discharge and reduce follow-up loss within 6 months.
What is the primary goal of the CHA "Test to Treat" program?
Prompts/reminders, education, and a navigator/care team model.
What does the CHA "Test to Treat" model consist of?
Patients, healthcare providers, and hospital systems.
Who does the CHA "Test to Treat" initiative target?
Must be a member of the CardioHealth Alliance.
What is the site requirement for participating in "Test to Treat"?
This program anticipates better LDL-C testing and achieved LDL-C, greater use of guideline-directed therapies, and improved follow-up after discharge.
What is CHA Test to Treat?
The effectiveness of a holistic, patient-centered, team-based approach to cardiometabolic disease care.
What is the CMCA initiative?
A collaborative care model involving pharmacists, APPs, and coordinated primary care teams.
What tools does the CMCA initiative utilize to implement care models?
ASCVD patients, pharmacists, and APPs in primary care.
Who are the key participants in the CMCA initiative?
Membership in the Cardiometabolic Center Alliance.
What is needed to participate in CMCA?
This initiative aims to demonstrate the effectiveness of a team-based care model on LDL-C and cardiometabolic outcomes.
What is CMCA?
To examine and track lipid-lowering therapy use and LDL-C levels in adults with ASCVD across 25 health systems over five years.
What is the aim of the cvMOBIUS2 registry project?
A prospective registry/performance dashboard in the PCORNET-based EHR data and willing to work with Duke Clinical Research Institute.
What kind of data does the cvMOBIUS2 registry rely on?
Providers and systems using PCORNET EHR and Duke Clinical Research Institute.
Who benefits from the cvMOBIUS2 registry project?
Use of PCORNET EHR and collaboration with Duke Clinical Research Institute.
What qualifies a site for cvMOBIUS2 participation?
This registry project expects to enhance adherence to guidelines and provide insights into lipid-lowering therapy patterns.
What is cvMOBIUS2?
To evaluate a site-level intervention that improves clinician adherence to LDL-C guidelines for very high-risk ASCVD patients.
What is the goal of the LOGAN-CV study?
Through computerized decision support tools and education modules and performance dashboards.
How does the LOGAN-CV study promote guideline-concordant care?
Clinicians within the Premier Network.
Who is the target audience for the LOGAN-CV study?
Sites in the Premier Network using the Premier Performance Dashboard.
Who can participate in the LOGAN-CV study?
This study predicts an increase in patients achieving LDL-C <70 mg/dL and stronger clinician adherence to treatment guidelines.
What is LOGAN-CV?